IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours

Amary, M Fernanda, Bacsi, Krisztian, Maggiani, Francesca, Damato, Stephen, Halai, Dina, Berisha, Fitim, Pollock, Robin, O'Donnell, Paul +8 more·2011·The Journal of Pathology
DOI 10.1002/path.2913

Cited by (1,000)

Items 201–300 of 1,000

  1. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds
    Fangrui Wu, Hong Jiang, Baisong Zheng, Mari Kogiso, Yuan Yao, Chao Zhou, Xiao‐Nan Li, Yongcheng Song · 2015 · Journal of Medicinal Chemistry
  2. Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
    Frank G. Schaap, Pim J. French, Judith V.M.G. Bovée · 2012 · Advances in Anatomic Pathology
  3. Succinate dehydrogenase deficiency is associated with decreased 5-hydroxymethylcytosine production in gastrointestinal stromal tumors: implications for mechanisms of tumorigenesis
    Emily Ferguson Mason, Jason L. Hornick · 2013 · Modern Pathology
  4. Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance
    Karen A. Boehme, Sabine Schleicher, Frank Traub, Bernd Rolauffs · 2018 · International Journal of Molecular Sciences
  5. Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells
    Stefano Bartesaghi, Vincenzo Graziano, Sara Galavotti, Nick V. Henriquez, Joanne Betts, Jayeta Saxena, Valentina Minieri, Deli A, Anna Karlsson, L. Miguel Martins et al. · 2015 · Proceedings of the National Academy of Sciences
  6. Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate
    Amir Tahmasb Fathi, Hossein Sadrzadeh, Amy H. Comander, Michaela Jane Higgins, Aditya Bardia, Ashley Marie Perry, Meghan E. Burke, Regina M. Silver, Christina R. Matulis, Kimberly S. Straley et al. · 2014 · The Oncologist
  7. Clinical impact of molecular biomarkers in gliomas
    Tali Siegal · 2014 · Journal of Clinical Neuroscience
  8. Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcoma
    Makoto Nakagawa, Fumihiko Nakatani, Hironori Matsunaga, Takahiko Seki, Makoto Endo, Yoko Ogawara, Yukino Machida, Takuo Katsumoto, Kazutsune Yamagata, Ayuna Hattori et al. · 2019 · Oncogene
  9. The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
    Alessandra Scagliola, Francesco Mainini, Simone Cardaci · 2019 · Antioxidants and Redox Signaling
  10. The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells
    Jing-Yi Chen, You-Syuan Lai, Hui‐Jen Tsai, Cheng-Chin Kuo, Betty Linju Yen, Su‐Peng Yeh, H. Sunny Sun, Wen-Chun Hung · 2016 · Scientific Reports
  11. Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
    Rui Ma, Cai‐Hong Yun · 2018 · Biochemical and Biophysical Research Communications
  12. Androgen receptor reverses the oncometabolite R-2-hydroxyglutarate-induced prostate cancer cell invasion via suppressing the circRNA-51217/miRNA-646/TGFβ1/p-Smad2/3 signaling
    Hua Xu, Yin Sun, Bosen You, Chi‐Ping Huang, Dingwei Ye, Chawnshang Chang · 2019 · Cancer Letters
  13. R132C IDH1 Mutations Are Found in Spindle Cell Hemangiomas and Not in Other Vascular Tumors or Malformations
    Kyle C. Kurek, Twinkal C. Pansuriya, Maayke A.J.H. van Ruler, Brendy van den Akker, Valerie L. Luks, Sofie Verbeke, Harry P. Kozakewich, Raf Sciot, Dina Chelouche Lev, Alexander J. Lazar et al. · 2013 · American Journal Of Pathology
  14. Prevalence of cartilaginous tumours as an incidental finding on MRI of the knee
    on behalf of the NEO study group, Wouter Stomp, M. Reijnierse, M. Kloppenburg, Renée de Mutsert, Judith V.M.G. Bovée, Martin den Heijer, Johan L. Bloem · 2015 · European Radiology
  15. Novel NTRK3 Fusions in Fibrosarcomas of Adults
    Fumito Yamazaki, Fumihiko Nakatani, Naofumi Asano, Susumu Wakai, Masaya Sekimizu, Sachiyo Mitani, Takashi Kubo, Akira Kawai, Hitoshi Ichikawa, Akihiko Yoshida · 2018 · The American Journal of Surgical Pathology
  16. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors
    Antje Wick, Oliver Bähr, Martin Schüler, Kristoffer Staal Rohrberg, Sant P. Chawla, Filip Jankú, David Schiff, Volker Heinemann, Yoshitaka Narita, Heinz‐Josef Lenz et al. · 2021 · Clinical Cancer Research
  17. Mitochondrial NADP+-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury
    Sang Jun Han, Hee‐Seong Jang, Mi Ra Noh, Jinu Kim, Min Jung Kong, Jee In Kim, Jeen‐Woo Park, Kwon Moo Park · 2016 · Journal of the American Society of Nephrology
  18. IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas
    Arjen H.G. Cleven, Johnny Suijker, Georgios Agrogiannis, Inge H. Briaire‐de Bruijn, Norma Frizzell, Attje S. Hoekstra, Pauline M. Wijers‐Koster, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2017 · Clinical Sarcoma Research
  19. Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes
    Yonghui Jin, Hassan Elalaf, Makoto Watanabe, Sakura Tamaki, Sho Hineno, Kazuhito Matsunaga, Knut Woltjen, Yukiko Kobayashi, Sanae Nagata, Makoto Ikeya et al. · 2015 · PLoS ONE
  20. Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
    Alexandra Borodovsky, Meghan J. Seltzer, Gregory Joseph Riggins · 2011 · Current Opinion in Oncology
  21. IDH1 mutations are not found in cartilaginous tumours other than central and periosteal chondrosarcomas and enchondromas
    Stephen Damato, Mohammed Sayel Alorjani, Fiona Bonar, Stanley W. McCarthy, Stephen R. Cannon, Paul O’Donnell, Roberto Tirabosco, Fernanda M Amary, Adrienne Margaret Flanagan · 2011 · Histopathology
  22. IDH1: Linking Metabolism and Epigenetics
    Silvia Raineri, Jane Mellor · 2018 · Frontiers in Genetics
  23. Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
    Jolieke G. van Oosterwijk, Maayke A.J.H. van Ruler, Inge H. Briaire‐de Bruijn, Bram Herpers, Hans A. J. Gelderblom, Bob van de Water, Judith V.M.G. Bovée · 2013 · British Journal of Cancer
  24. Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases
    Nadjla Alsadoun, Gaëtan Marie MacGrogan, Caroline Truntzer, Magali Lacroix‐Triki, Isabelle Bedgedjian, Marie-Hélène Koeb, Elsy El Alam, Dan Médioni, Michel Parent, Pascal Wuithier et al. · 2018 · Modern Pathology
  25. Oncogenic Metabolism Acts as a Prerequisite Step for Induction of Cancer Metastasis and Cancer Stem Cell Phenotype
    Su Yeon Lee, Min Kyung Ju, Hyun Min Jeon, Yig Ji Lee, Cho Hee Kim, Hye Gyeong Park, Song Iy Han, Ho Sung Kang · 2018 · Oxidative Medicine and Cellular Longevity
  26. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death
    Isabelle Vanessa Mohrenz, Patrick Antonietti, Stefan Pusch, David Capper, Jörg Balß, Sophia Voigt, Susanne Weißert, Alicia Mukrowsky, Jan Frank, Christian Senft et al. · 2013 · APOPTOSIS
  27. Targeting the Apoptotic Pathway in Chondrosarcoma Using Recombinant Human Apo2L/TRAIL (Dulanermin), a Dual Proapoptotic Receptor (DR4/DR5) Agonist
    Vivek Subbiah, Robert Eldon Brown, Jamie Buryanek, Jonathan C. Trent, Avi Ashkenazi, Roy S. Herbst, Razelle Kurzrock · 2012 · Molecular Cancer Therapeutics
  28. Tumors of soft tissue and bone
    Peiguo G. Chu, Lawrence Martin Weiss · 2000 · Cambridge University Press eBooks
  29. Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma
    Adrián Mariño‐Enríquez, Judith V.M.G. Bovée · 2016 · Surgical pathology clinics
  30. Chordoma of the Head and Neck: A Review
    Jason K. Wasserman, Denis H. Gravel, Bibianna Purgina · 2017 · Head and Neck Pathology
  31. Searching for molecular targets in sarcoma
    Beverly A. Teicher · 2012 · Biochemical Pharmacology
  32. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas
    Jeffrey K. Mito, Justin A. Bishop, Peter M. Sadow, Edward B. Stelow, William C. Faquin, Stacey E. Mills, Jeffrey F. Krane, Christopher Alexander French, Christopher D.�M. Fletcher, Jason L. Hornick et al. · 2018 · The American Journal of Surgical Pathology
  33. Chemotherapy for Bone Sarcoma in Adults
    Michael J. Wagner, John Andrew Livingston, SHREYASKUMAR R. PATEL, Robert S. Benjamin · 2016 · Journal of Oncology Practice
  34. Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate
    Jörg Balß, Stefan Pusch, Ann-Christin Beck, Christel C. Herold‐Mende, Alwin Krämer, Christian Thiede, Wolfgang Buckel, Claus‐Dieter Langhans, Jürgen G. Okun, Andreas von Deimling · 2012 · Acta Neuropathologica
  35. Correlation between IDH, ATRX, and TERT promoter mutations in glioma
    Shigeo Ohba, Kiyonori Kuwahara, Seiji Yamada, Masato Abe, Yuichi Hirose · 2020 · Brain Tumor Pathology
  36. IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
    Daniel Krell, Paul James Mulholland, Adam Enver Frampton, Jonathan Krell, Justin Stebbing, Chiara Bardella · 2013 · Future Oncology
  37. Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
    Yang Liu, Fengchao Lang, Fu-Ju Chou, Kareem A. Zaghloul, Chunzhang Yang · 2020 · Biomedicines
  38. Cancer-associated 2-oxoglutarate analogues modify histone methylation by inhibiting histone lysine demethylases
    Tuomas Laukka, Matti Myllykoski, Ryan Looper, Peppi Koivunen · 2018 · Journal of Molecular Biology
  39. IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies
    Elisa Bergaggio, Chiara Riganti, Giulia Garaffo, Nicoletta Vitale, Elisabetta Mereu, Cecilia Bandini, Elisa Pellegrino, Verdiana Pullano, Paola Omedè, Katia Todoerti et al. · 2018 · Blood
  40. IDH2 Mutation Analysis in Undifferentiated and Poorly Differentiated Sinonasal Carcinomas for Diagnosis and Clinical Management
    Cristina Riobello, Alejandro López‐Hernández, Virginia N. Cabal, Rocío García‐Marín, Laura Suárez–Fernández, Paula Sánchez‐Fernández, Blanca Vivanco, Verónica Blanco, Fernando López, Alessandro Franchi et al. · 2019 · The American Journal of Surgical Pathology
  41. Cholangiocarcinoma: risk factors, environmental influences and oncogenesis.
    Redha Al-Bahrani, Yasser Abuetabh, Nikolas Zeitouni, Consolato Maria Sergi · 2013 · PubMed
  42. Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity
    Zhen Liu, Yuan Yao, Mari Kogiso, Baisong Zheng, Lisheng Deng, Jihui Julia Qiu, Shuo Dong, Hua Lv, James M. Gallo, Xiao‐Nan Li et al. · 2014 · Journal of Medicinal Chemistry
  43. Novel Modes of Inhibition of Wild-Type Isocitrate Dehydrogenase 1 (IDH1): Direct Covalent Modification of His315
    Clarissa G. Jakob, Anup K. Upadhyay, Pamela L. Donner, Emily Nicholl, Sadiya N. Addo, Wei Qiu, Christopher Ling, Sujatha M. Gopalakrishnan, Maricel Torrent, Steven P. Cepa et al. · 2018 · Journal of Medicinal Chemistry
  44. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia
    Ogawara, Yoko, Katsumoto, Takuo, Aikawa, Yukiko, Shima, Yutaka, Kagiyama, Yuki, Soga, Tomoyoshi, Matsunaga, Hironori, Seki, Takahiko, Araki, Kazushi, Kitabayashi, Issay · 2015 · Cancer Research
  45. Immunohistochemical analysis of IDH2 R172 hotspot mutations in breast papillary neoplasms: applications in the diagnosis of tall cell carcinoma with reverse polarity
    Fresia G. Pareja, Edaise M. da Silva, Denise Frosina, Felipe Correa Geyer, John R. Lozada, Thais Basili, Arnaud Da Cruz Paula, Elaine Zhong, Fatemeh N. Derakhshan, Timothy M. D’Alfonso et al. · 2020 · Modern Pathology
  46. Cartilage-forming tumors
    Shadi A. Qasem, Barry R. DeYoung · 2014 · Seminars in Diagnostic Pathology
  47. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone
    Shaoxiong Chen, Karen Fritchie, Shi Wei, Naser M. Ali, Kendra L. Curless, Tiansheng Shen, Anna Teresa Brini, Farida Latif, Vaiyapuri P. Sumathi, Gene P. Siegal et al. · 2017 · Human Pathology
  48. The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
    Iman Abou Dalle, Courtney Denton Dinardo · 2018 · Therapeutic Advances in Hematology
  49. A Potent Blood–Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model
    Yukino Machida, Makoto Nakagawa, Hironori Matsunaga, Masayuki Yamaguchi, Yoko Ogawara, Yutaka Shima, Kazutsune Yamagata, Takuo Katsumoto, Ayuna Hattori, Masato Itoh et al. · 2019 · Molecular Cancer Therapeutics
  50. The impact of osteoblastic differentiation on osteosarcomagenesis in the mouse
    Tyler S. Quist, H Jin, J-F Zhu, Kyllie Smith-Fry, Mario R. Capecchi, Kevin B. Jones · 2014 · Oncogene
  51. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma
    Gavin P. Dunn, Ovidiu C. Andronesi, Daniel P. Cahill · 2013 · Neurosurgical FOCUS
  52. Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype
    Elisabet Cuyàs, Salvador Fernández‐Arroyo, Bruna Corominas-Faja, Esther Rodríguez‐Gallego, Joaquim Bosch‐Barrera, Begoña Martı́n-Castillo, Rafel Llorens, Jorge Joven, Javier Abel Menéndez · 2015 · Oncotarget
  53. Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG
    Anna Catharina Navis, Simone P. Niclou, Fred Fack, Daniel Stieber, Sanne A. M. van Lith, Kiek N. Verrijp, Alan J. Wright, Jonathan Stauber, Bastiaan B.J. Tops, Irene Otte‐Höller et al. · 2013 · Acta Neuropathologica Communications
  54. Connections between metabolism and epigenetics: mechanisms and novel anti-cancer strategy
    Chen Chen, Zehua Wang, Yanru Qin · 2022 · Frontiers in Pharmacology
  55. Lessons from next-generation sequencing analysis in hematological malignancies
    Esteban Braggio, Jan B. Egan, Rafaël Fonseca, A. Keith Stewart · 2013 · Blood Cancer Journal
  56. SHP2 Regulates Chondrocyte Terminal Differentiation, Growth Plate Architecture and Skeletal Cell Fates
    Margot E. Bowen, Ugur M. Ayturk, Kyle C. Kurek, Wentian Yang, Matthew L. Warman · 2014 · PLoS Genetics
  57. Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
    Ingvild Comfort Hvinden, Tom A.D. Cadoux-Hudson, Christopher John Schofield, James McCullagh · 2021 · Cell Reports Medicine
  58. Mutant IDH in Gliomas: Role in Cancer and Treatment Options
    Georgios Solomou, Alina Finch, Asim Asghar, Chiara Bardella · 2023 · Cancers
  59. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth
    Shenghong Ma, Bowen Jiang, Wanglong Deng, Zhong-Kai Gu, Fei-Zhen Wu, Tingting Li, Yukun Xia, Hui Yang, Dan Ye, Yue Xiong et al. · 2015 · Oncotarget
  60. Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
    Anna Eriksson, Andreas Lennartsson, Sören Lehmann · 2015 · Experimental Hematology
  61. The clinical use of IDH1 and IDH2 mutations in gliomas
    Alberto Pïcca, Giulia Berzero, Anna Luisa Di Stefano, Marc Sanson · 2018 · Expert Review of Molecular Diagnostics
  62. Epigenetics as a New Frontier in Orthopedic Regenerative Medicine and Oncology
    André J. van Wijnen, Jennifer J. Westendorf · 2019 · Journal of Orthopaedic Research®
  63. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
    Elisabeth F.P. Peterse, Bertine Niessen, Ruben D. Addie, Yvonne de Jong, Arjen H.G. Cleven, Alwine B. Kruisselbrink, Brendy E.W.M. van den Akker, Remco Jurriaan Molenaar, Anne‐Marie Cleton-Jansen, Judith V.M.G. Bovée · 2018 · British Journal of Cancer
  64. Molecular Markers in Low-Grade Glioma—Toward Tumor Reclassification
    Adriana Olar, Erik P. Sulman · 2015 · Seminars in Radiation Oncology
  65. The good, the bad and the ugly: Epigenetic mechanisms in glioblastoma
    Helena Carén, Steven M. Pollard, Stephan Beck · 2012 · Molecular Aspects of Medicine
  66. Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma
    Annemiek M. van Maldegem, Anthony Paul Conley, Piotr Lukasz Rutkowski, SHREYASKUMAR R. PATEL, Iwona A. Lugowska, Ingrid M.E. Desar, Judith V.M.G. Bovée, Hans A. J. Gelderblom · 2018 · The Oncologist
  67. Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis
    Huy Gia Vuong, Tam N.M. Ngo, Ian F. Dunn · 2021 · Cancer Medicine
  68. The Tricarboxylic Acid Cycle Metabolites for Cancer: Friend or Enemy
    Jie Wu, Nian Liu, Jing Chen, Qian Tao, Qiuqiu Li, Jie Li, Xiang Chen, Cong Peng · 2024 · Research
  69. FGFR3 Deficiency Causes Multiple Chondroma-like Lesions by Upregulating Hedgehog Signaling
    Siru Zhou, Yangli Xie, Junzhou Tang, Junlan Huang, Qizhao Huang, Wei Xu, Zuqiang Wang, Fengtao Luo, Quan Wang, Hangang Chen et al. · 2015 · PLoS Genetics
  70. Impaired TCA cycle flux in mitochondria in skeletal muscle from type 2 diabetic subjects: Marker or maker of the diabetic phenotype?
    Michael Gaster, Jan Olof Nehlin, Ariane Denise Minet · 2012 · Archives of Physiology and Biochemistry
  71. Application of liquid biopsy in bone and soft tissue sarcomas: Present and future
    Li, Xiaoyang, Seebacher, Nicole A., Hornicek, Francis J., Xiao, Tao, Duan, Zhenfeng · 2018 · Cancer Letters
  72. Differential Diagnosis of Cartilaginous Lesions of Bone
    David Ilan Suster, Yin Pun Hung, G. Petur Nielsen · 2019 · Archives of Pathology & Laboratory Medicine
  73. Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi‐specific monoclonal antibody MsMab‐1
    Xing Liu, Yukinari Kato, Mika Kato Kaneko, Masato Sugawara, Satoshi Ogasawara, Yuta Tsujimoto, Yasushi Naganuma, Mitsunori Yamakawa, Takashi Tsuchiya, Michiaki Takagi · 2013 · Cancer Medicine
  74. Elevated d -2-hydroxyglutarate during colitis drives progression to colorectal cancer
    Jie Han, Dakota N. Jackson, Janette Holm, Kevin Turner, Paula Ashcraft, Xuan Wang, Beth N Cook, Erland Arning, Robert Maximilian Genta, K. Venuprasad et al. · 2018 · Proceedings of the National Academy of Sciences
  75. Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy
    Elisa Bergaggio, Roberto Piva · 2019 · Cancers
  76. IDH1, a CHOP and C/EBPβ-responsive gene under ER stress, sensitizes human melanoma cells to hypoxia-induced apoptosis
    Xuejun Yang, Tongde Du, Xiang Wang, Yingqiu Zhang, Wanglai Hu, Xiaofeng Du, Lin Miao, Chuanchun Han · 2015 · Cancer Letters
  77. Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas
    Fernanda M Amary, Hongtao Ye, Georgina Forbes, Stephen Damato, Francesca Maggiani, Rob C. Pollock, Roberto Tirabosco, Adrienne Margaret Flanagan · 2014 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  78. Glutamate as chemotactic fuel for diffuse glioma cells: Are they glutamate suckers?
    Sanne A. M. van Lith, Anna Catharina Navis, Kiek N. Verrijp, Simone P. Niclou, Rolf Bjerkvig, Pieter Wesseling, Bastiaan B.J. Tops, Remco Jurriaan Molenaar, Cornelis J.F. Van Noorden, William P. J. Leenders · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
  79. Proximity ligation assay evaluates IDH1R132H presentation in gliomas
    Lukas Bunse, Theresa Schumacher, Felix Sahm, Stefan Pusch, Iris Oezen, Katharina J. Rauschenbach, Marina Gonzalez, Gergely Morten Solecki, Matthias Osswald, David Capper et al. · 2015 · Journal of Clinical Investigation
  80. Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
    Ramona Bledea, Varshini Vasudevaraja, Seema V. Patel, James M. Stafford, Jonathan Serrano, Gianna Esposito, Lilian M. Tredwin, Nina E. Goodman, Andreas Kloetgen, John G. Golfinos et al. · 2019 · Scientific Reports
  81. Molecular oncogenesis of chondrosarcoma: impact for targeted treatment
    Frank M. Speetjens, Yvonne de Jong, Hans A. J. Gelderblom, Judith V.M.G. Bovée · 2016 · Current Opinion in Oncology
  82. Current questions in bone sarcomas
    Sandra J. Strauss, Jeremy Whelan · 2018 · Current Opinion in Oncology
  83. Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes
    Yvonne de Jong, Martha Ingola, Inge H. Briaire‐de Bruijn, Alwine B. Kruisselbrink, Sanne Venneker, Ieva Palubeckaitė, Bram Heijs, Anne‐Marie Cleton-Jansen, Rick L. M. Haas, Judith V.M.G. Bovée · 2019 · Clinical Sarcoma Research
  84. Discovery and Optimization of Quinolinone Derivatives as Potent, Selective, and Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors
    Jian Lin, Wei Lu, Justin A. Caravella, Ann Marie Campbell, R. Bruce Diebold, Anna M. Ericsson, Edward L. Fritzen, Gary R. Gustafson, David R. Lancia, Tatiana E. Shelekhin et al. · 2019 · Journal of Medicinal Chemistry
  85. Myoepithelial Tumors
    Vickie Y. Jo · 2015 · Surgical pathology clinics
  86. Oncogenic IDH mutations increase heterochromatin-related replication stress without impacting homologous recombination
    Juan M. Schvartzman, Grace Forsyth, Henry S. Walch, Walid Khaled Chatila, Angelo Taglialatela, Brian J. Lee, Xiaolu Zhu, Steven Gershik, Francesco V. Cimino, Anthony Santella et al. · 2023 · Molecular Cell
  87. Novel Therapeutic Targets of Tumor Metabolism
    Rigel J. Kishton, Jeffrey C. Rathmell · 2015 · The Cancer Journal
  88. Whole‐exome sequencing detects somatic mutations of IDH1 in metaphyseal chondromatosis with D ‐2‐hydroxyglutaric aciduria (MC‐HGA)
    Lisenka E.L.M. Vissers, Virginia Fano, Diego Martinelli, Belinda Campos‐Xavier, Domenico Barbuti, Tae‐Joon Cho, Ahmet Dursun, Ok Hwa Kim, Sun Hee Lee, Giuseppina Timpani et al. · 2011 · American Journal of Medical Genetics Part A
  89. The potential of breath analysis to improve outcome for patients with lung cancer
    Sophia Antoniou, Edoardo Gaude, Mamta Ruparel, Marc P. van der Schee, Sam M. Janes, Robert Campbell Rintoul · 2019 · Journal of Breath Research
  90. Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma
    Tania L. Slatter, Howard Hsia, Ari Samaranayaka, Peter H. Sykes, W. M. Clow, Celia J. Devenish, T. Sutton, Janice A. Royds, Philip P.C. Ip, Any Cheung et al. · 2015 · The Journal of Pathology Clinical Research
  91. Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications
    Ruta Gupta, Rebecca Webb-Myers, Simon Flanagan, Michael E. Buckland · 2011 · Journal of Clinical Pathology
  92. Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate
    Anuhar Chaturvedi, Michelle Maria Araujo Cruz, Nidhi Jyotsana, A Sharma, Ramya Goparaju, Adrian Schwarzer, Kerstin Görlich, Renate Schottmann, Eduard A. Struys, Erwin E. W. Jansen et al. · 2016 · Leukemia
  93. Management of isocitrate dehydrogenase 1/2 mutated acute myeloid leukemia
    Harry Fruchtman, Zachary M. Avigan, Julian A. Waksal, Nicole Brennan, John O Mascarenhas · 2024 · Leukemia
  94. Clinical Relevance of Prognostic and Predictive Molecular Markers in Gliomas
    Tali Siegal · 2015 · Advances and technical standards in neurosurgery
  95. Extraskeletal Mesenchymal Chondrosarcoma
    Komal Arora, Nicole D. Riddle · 2018 · Archives of Pathology & Laboratory Medicine
  96. Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma
    Shinji Miwa, Norio Yamamoto, Katsuhiro Hayashi, Akihiko Takeuchi, Kentaro Igarashi, Hiroyuki Tsuchiya · 2022 · International Journal of Molecular Sciences
  97. DNA methylation in human diseases
    Samareh Younesian, Mohammad Hossein Mohammadi, Ommolbanin Younesian, Majid Momeny, Seyed Hamidollah Ghaffari, Davood Bashash · 2024 · Heliyon
  98. The Emerging Role of D-2-Hydroxyglutarate as an Oncometabolite in Hematolymphoid and Central Nervous System Neoplasms
    Dinesh Rakheja, Leonard Jeffrey Medeiros, Scott Bevan, Weina Chen · 2013 · Frontiers in Oncology
  99. Giant Cell Lesions of the Craniofacial Bones
    Adrienne Margaret Flanagan, Paul Michael Speight · 2014 · Head and Neck Pathology
  100. DNA Sequencing of Cancer: What Have We Learned?
    Juliann Chmielecki, Matthew M. Meyerson · 2013 · Annual Review of Medicine